A novel synthetic nucleic acid for the development of a vaccine against human Respiratory Syncytial Virus
We have modified a gene from human RSV which results in the generation of neutralising antibodies and a long-lived and robust protective response against RSV infection
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
